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Abstract: Background: Throughout history, menopause has been regarded as a transition in a
woman’s life. With the increase in life expectancy, women now spend more than a third of their lives
in menopause. During these years, women may experience intolerable symptoms both physically and
mentally, leading them to seek clinical advice. It is imperative for healthcare providers to improve
the quality of life by reducing bothersome menopausal symptoms and preventing disorders such as
osteoporosis and atherosclerosis. The current treatment in the form of hormone replacement therapy
(HRT) is sometimes inadequate with several limitations and adverse effects. Objective and rationale:
The current review aims to discuss the need, efficacy, and limitations of current HRT; the role of
other ovarian hormones, and where we stand in comparison with ovary-in situ; and finally, explore
towards the preparation of an HRT model by regeneration of ovaries tissues through stem cells which
can replicate a functional ovary. Search methods: Four electronic databases (MEDLINE, Embase,
Web of Science and CINAHL) were searched from database inception until 26 April 2018, using a
combination of relevant controlled vocabulary terms and free-text terms related to ‘menopause’,
‘hormone replacement therapy’, ‘ovary regeneration’, ‘stem cells’ and ‘ovarian transplantation’.
Outcomes: We present a synthesis of the existing data on the efficacy and limitations of HRT. HRT is
far from adequate in postmenopausal women with symptoms of hormone deprivation as it fails to
deliver all hormones secreted by naïve ovarian tissue. Moreover, the pharmacokinetics of synthetic
hormones makes them substantially different from natural ones. Not only does the number and
type of hormones given in HRT matter, but the route of delivering and their release in circulation
are also imperative. The hormones are delivered either orally or topically in a non-physiological
uniform manner, which brings along with it several side effects. These identify the need for a
hormone delivery system which replicates, integrates and reacts as per the requirement of the female
body. Wider implications: The review outlines the strengths and weaknesses of HRT and highlights
the potential areas for future research. There is a tremendous potential for research in this field to
understand the collective roles of the various ovarian hormones and to devise an auto-regulated
hormone delivery system which replicates the normal physiology. Its clinical applications can prove
to be transformative for postmenopausal women helping them to lead a healthy and productive life.
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1. Background
Throughout history, menopause has been regarded as a major transition in a woman’s life.
With the increase in life expectancy, women now spend more than a third of their life in menopause.
During these years, women experience intolerable symptoms and seek clinical advice. It is imperative
for healthcare providers to improve the quality of lives by reducing bothersome menopausal
symptoms and preventing disorders such as osteoporosis, atherosclerosis and coronary heart disease,
dyslipidemia, and so on. However, a question that is yet to be determined is: “Is the age of natural
menopause a marker of health and aging?” The onset of menopause has been considered as an ideal
time to introduce preventative strategies to improve the longevity and quality of postmenopausal
women’s lives. The current hormone replacement therapy (HRT), which is primarily based on estrogen
and progesterone, has been prescribed over decades for the treatment of postmenopausal symptoms,
and has been questioned time and again owing to its side effects and efficacy in substituting for
a functional ovary. Recent developments in estrogen and progesterone-based drugs and mode
of deliveries have extended the benefits of HRT; however, it is yet to be equivalent to functional
ovaries of premenopausal women. Along with releasing eggs, ovaries secrete several hormones,
including oestrogen, progesterone, testosterone, activin, inhibin, anti-Müllerian hormone (AMH) and
insulin-like growth factor 1 (IGF-1), which have an immense significance on a woman’s physiology [1].
The secretion and functioning of these hormones are complexly integrated and intricately regulated
by many positive and negative feedback loops (Figure 1). Hence, the ovary must not be regarded
as a static endocrine organ, which expands at puberty and contracts with menopause, rather, it is a
dynamic organ whose periodicity is measured in weeks. It has immensely beneficial effects on women’s
health and is considered to be the prime attribute for lower morbidity and mortality, as evidenced
in premenopausal women compared to men of the same age group. Later age at natural menopause
has been found to be associated with plenty of benefits, including longevity and reduced all-cause
mortality [2–4]. There is a decreased prevalence of atherosclerosis and cardiovascular events in women
with late age at natural menopause [5–9]. Moreover, there are some additional benefits, such as a
substantial increase in the bone density and consequently a reduction in the incidence of osteoporosis
and fractures [10,11]. Nevertheless, it comes at a cost of increased risk of breast [12], ovarian [3,13] and
endometrial [14] cancers. However, unlike a functional ovary, the exogenous hormones, oestrogen and
progesterone, prescribed during the postmenopausal period in a stereotyped manner to replete the
functioning of in situ ovary bring along several side effects.
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Figure 1. Schematic representati of the l vel of vari us ovarian hormones in reproductive age,
post- enopausal and in women on HRT.
The present review intends to discuss the need, efficacy, and limitations of current oestrogen- and
progesterone-based HRT; where we stand in comparison with a functioning ovary in situ; and finally,
to explore towards the preparation of an ideal HRT model which can truly replicate a functional
ovary. We have evaluated the published literature on the benefits and risks associated with HRT,
and the importance of other hormones secreted by the functioning premenopausal ovary which are
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not currently included in the HRT. We have further explored the emerging opportunities for the
development of a flawless HRT model, which could help post-menopausal women to battle through
this period, and which could be achieved by understanding the role, mode and regulation of all
hormones secreted by functioning ovaries, improving the present oestrogen- and progesterone-based
drugs and their delivery system.
2. Health Concerns with Menopause/Need for HRT
The health problems of women undergoing menopause are varied, ranging from mild mood
issues to severe problems such as myocardial infarction, and are amenable to treatment to varying
degrees by HRT. They are discussed in detail in the following paragraphs (Figure 2).
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2.1. Coronary Artery Disease
Heart disease is the leading cause of death for women in the developed world [15]. Before the
age of 40 years, women have a lower incidence of coronary heart disease (CHD) and myocardial
infarction than men (WHO 2009). The lower incidence in premenopausal women is attributed to the
favourable effect of oestrogen on the lining of the blood vessels, the endothelium [16,17]. However,
following me op use, the ben fit slowly fad s, and women are t a similar isk f dying from
cardiovascular diseases s me . Similarly, women with premature ovarian failure are at an increased
risk of CHD [18]. The increased risk with HRT was unveiled by Women’s Health Initiative (WHI) and
the Heart and Estrogen-progestin Replacement Study (HERS) I and HERS II studies [19–21]. In 2013,
WHI investigators reported age as a major attribute in the benefit-risk balance following hormone
use [22]. Presently, many observational studies suggest that if HRT is started immediately following
menopause, it has more beneficial effects on the cardiovascular health and leads to decreased mortality.
In contrast, the mortality due to heart diseases is increased if HRT is started more than 10 years after
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menopause or after the age of 60 years [23–25]. Thus, this ‘therapeutic window’ for starting HRT gives
a limitation to the use of HRT in the prevention of cardiac disease [26]. The prothrombotic effects
of oestrogen include a decrease in the levels of serum fibrinogen, factor VII, and antithrombin III.
These effects are less pronounced in case of transdermal oestrogen but the evidence that transdermal
oestrogen is safer for secondary prevention of CHD is lacking [27,28]. In addition, the choice and
regimen of progesterone is important as there is some evidence that some progesterone like medroxy
progesterone acetate (MPA) (used in WHI and HERS) might attenuate the cardiac benefit caused by
oestrogen while norethindrone acetate or natural progesterone are not found to lessen the benefit of
oestrogen. Studies have shown that combined oestrogen-progesterone therapy does not affect the
incidence of peripheral arterial events [29].
2.2. Metabolic Effects
The remarkable effects of oestrogen on women’s metabolism, and its elusive physiological shield
against metabolic syndrome in women of reproductive age making oestrogen the most likely candidate
for the HRT. The deficiency of oestrogen postmenopausally causes the development of metabolic
syndrome (41.5%) and hypertriglyceridemia (56.9%) in almost half of menopausal women [30–32].
Women with metabolic syndrome have six times increased risk of developing CHD and the underlying
pathophysiology could be related to insulin resistance or central obesity [33]. HRT, instead of restoring the
imbalance, further worsens some of the metabolic effects like hypertriglyceridemia, while decreasing
low-density lipoprotein and increasing high-density lipoprotein levels [34]. It is notable that HRT
appears to decrease the risk of diabetes mellitus type 2; however, the impact is insufficient for HRT to
be recommended for its prevention [35,36].
2.3. Osteoporosis
Osteoporosis is widely recognised as one of the most common bone problems in elderly females.
It is a generalised skeletal disorder ascribed to decreased bone mass with increased susceptibility
to fractures. Seventy-five percent or more of bone mass loss has been attributed to the declining
oestrogen levels during the postmenopausal period, rather than aging [37]. Oestrogen exerts a constant
suppressive action on the remodelling of bone and with reduced oestrogen levels in menopause.
The bone resorption is enhanced by oestrogen. The risk of sustaining a fracture in a postmenopausal
woman is almost twice the lifetime probability of developing breast cancer for a woman [38–40].
Although HRT is not the first line treatment in postmenopausal women for the prevention or
treatment of osteoporosis, WHI study revealed a significant reduction in fractures in women on HRT
compared to women on placebo [41]. While, HRT is effective in osteoporosis, it is not uniformly
recommended by all the major societies for its prevention [42–45].
2.4. Vasomotor Symptoms (VMS)
Commonly known as hot flushes or night sweats (VMS) are experienced by about 60–80% of
postmenopausal women during the perimenopausal phase [46–48]. Most importantly, VMS severely
affect women’s sense of wellbeing and quality of life [49,50]. According to a Cochrane review, there was a
significant reduction in the frequency and severity of hot flushes with HRT as compared to placebo [51,52].
HRT is recommended for women with moderate to severe symptoms and no contraindications for
short-term symptom relief. It can be speculated that the other ovarian hormones also play a potential
role in triggering these symptoms.
2.5. Vulvovaginal Atrophy (VVA)
Oestrogen deficiency results in atrophy of the vaginal mucosa, causing vaginal dryness,
dyspareunia (painful intercourse), itching, vaginal stenosis and urinary incontinence. Similar to VMS,
VVA is highly prevalent among postmenopausal women, with prevalence ranging from 4% in early
menopause to 47% by three years after the last menses [53]. Low-dose vaginal oestrogen preparations
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are shown to be highly efficacious in treating VMS [54]. The American College of Obstetricians and
Gynaecologists and North American Menopause Society recommend the indefinite use of low-dose
vaginal therapy for as long as needed; however, there is limited evidence regarding the safety of vaginal
preparations beyond one year of use [55,56]. Similarly, another study was recently published reassuring
the long-term safety of vaginal oestrogen [57].
The incidence of urinary tract infections and the symptoms of overactive bladder are found
to decrease with topical oestrogen therapy [54,58]. Urinary incontinence affects 26–40% of women
beyond the age of 55 years [59]. It is hypothesised that oestrogen plays a vital role in the continence
mechanism; however, randomised control trials (RCTs) have failed to demonstrate improvement
in urinary incontinence in post-menopausal females following treatment with oestrogen [60–62].
In contrast, HERS reported an increase in incontinence with HRT [63]. The worsening of symptoms
with exogenous administration of oestrogen is an enigma as biological oestrogen secreted by the ovary
is protective, as evidenced by a lower incidence in younger women [59].
2.6. Cognition and Dementia
Studies have reported that dementia occurs less frequently in oestrogen users and the preventive
effect is greater with increasing dose and duration of use [64–66]. Oestradiol replacement in rats
found that it increases the activity of choline acetyltransferase in various parts of the brain related to
memory and cognition [67]. Others have advocated a critical window period for starting HRT [68–70]
for dementia. No such difference was found in studies where HRT was given to older postmenopausal
females (>65 years) [71,72]. On the other hand, an increased risk of dementia was found when
oestrogen was given in combination with progesterone (HRT) [73]. A Cochrane review in 2008 has
refuted any benefits of HRT on cognition [74]. Another review reflected both possible beneficial and
detrimental impact of oestrogen on memory in the aging brain [75]. There appears to be no conclusive
study to give a definitive answer to this critical concern.
2.7. Sleep Disturbances
The quality of sleep deteriorates with aging [76], and menopause further contributes to it [77,78].
The Study of Women’s Health Across the Nation (SWAN) in the United States of America reported
sleep disturbances in 36.6% of late perimenopausal or postmenopausal women [79]. The role of HRT
is quite limited in treating sleep disorders associated with menopause.
2.8. Overall Effects of HRT
The ovary has an immense benefit for women’s health and is the primary organ responsible for
lowering morbidity and mortality in premenopausal women compared to men of the same age group.
However, the advantages gained through functioning ovaries, decline with menopause and HRT
does not appear to reap the expected benefits. Moreover, HRT, when prescribed for a long duration,
is associated with many side effects, some being life-threatening. Therefore, the benefits must be
weighed against the risks before prescribing HRT. Though it should be noted that long-term exposure
to endogenous hormones is also associated with increased risks. Further research is required not only
to validate these findings but also develop a novel hormone replacement model which can replicate
the natural functioning of ovary without causing the adverse effects.
3. Current Preparations of HRT in Clinical Practice
Current HRT mainly consists of oestrogen and progesterone in various preparations differing
in their dosages and routes of administration, each having its benefits and risks (Table 1). However,
with HRT, the menopausal symptoms can only be partially relieved, as present therapy fails to replicate
the natural functioning of an ovary. The relative alleviation of menopausal symptoms is primarily due
to oestrogen. The oestrogen only therapy is prescribed for a hysterectomised woman, but in a woman
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with an intact uterus, progestin is added to combat the increased risk of endometrial hyperplasia and
even carcinoma.
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Natural oestrogens are available in various plant sources like soy, but their efficacy is unclear.
The modified oestrogens are called semisynthetic and include conjugated oestrogens (conjugated
equine oestrogen, oestradiol valerate and oestrone sulphate) and micronized oestradiol. Conjugated
equine oestrogen is prepared from the urine of pregnant mares and is composed of 50–60% oestrone
sulphate along with other equine oestrogens like equilin and 17-dihydroequilin. Micronisation of
oestradiol results in higher blood levels of oestrogen, but it is rapidly metabolised to less active forms
like oestrone. Synthetic oestrogens such as ethinyl oestradiol have better potency and extended half-life.
Based on present evidence, physicians have unsuccessfully tried to tailor the HRT prescription
as per the symptoms of menopausal women. Women are informed that their prescription for HRT
has been individualised with the type and dosage of preparation being determined according to their
specific requirements. However, in reality, there are no means of establishing the amount of hormones
needed by a woman’s body to combat her postmenopausal symptoms. This is because the ovarian
physiology is dynamic and the blood levels of hormones could be misleading since every woman
develops symptoms at different hormone levels with varying severity.
Bio-Identical HRT (BHRT)
Over the last two decades, many people are attracted by the idea of bio-identical hormones (BHRT).
Bio-identical hormones are derived from plant extracts and chemically modified in the laboratory so
as to be identical in molecular structure to natural female hormones [80]. There have been attempts
to promote BHRT stating that these hormones are natural and, therefore, superior to synthetic HRT.
Nevertheless, studies have failed to prove BHRT to be superior to conventional HRT [81–83].
4. Adverse Effects of HRT
It has been established that HRT is far from adequate in treating women with menopausal
symptoms [52,84–86]. Moreover, it is associated with many unwanted and serious adverse effects,
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which are discussed subsequently. It is, however, important to note that these risks are also associated
with delayed menopause.
4.1. Venous Thromboembolism (VTE) and Stroke
Venous thromboembolism is characterised by the formation of thrombus in deep veins of legs,
which can embolise to the pulmonary circulation and even cause death. HRT increases the risk of VTE
by 2-fold, mostly in the first and second years of treatment [87]. Studies have shown that transdermal
oestrogen is associated with a lower risk while progesterone only HRT is not associated with an
increased risk of VTE [88,89]. There is a wealth of literature showing the increased incidence of
stroke in women on either oestrogen only or oestrogen-progestin HRT [90–92]. The current users of
transdermal or oral HRT have a higher risk of stroke than non-users [93]. Hence, caution must be
exercised in prescribing HRT to women with risk factors for stroke or VTE. The contention remains:
why does oestrogen in HRT increase the risk of VTE while the presence of a functioning ovary does not?
4.2. Gynaecological Cancers
There is an increased risk of breast cancer in users of present HRT [94]. Recent studies have
reported a hazard ratio of 1.24 to 2.74 in current users after 2 to 5 years of HRT use, which increases
further with increasing duration of use [95,96].
A woman’s risk of having ovarian cancer during her lifetime is 1–1.5% and dying from the same
disease is almost 0.5% [97]. A recent meta-analysis has revealed a relative risk of 1.43 in hormone users
compared to non-users [98]. They reported increased risk, even with a limited period of use (less than
five years), and the risk, although it declines, persists even ten years after discontinuing HRT. Women
on unopposed oestrogen only therapy have a non-significant decrease in the incidence of breast cancer
with a definite increased risk of endometrial cancer [22].
Endometrial carcinoma is the most common malignancy of the female genital tract, with 2–3% of
women developing the cancer in their lifetime [99]. The risk increases manifold by taking unopposed
oestrogen therapy; however, the threat of the cancer is almost entirely eliminated by the addition of
progestins in a continuous fashion [100–102].
5. Caveats with HRT
There are many relative contraindications to HRT, although no absolute contraindications
exist [103]. On the contrary, the presence of a normal functioning ovary in a woman causes less
harm (if any) while offering plenty of benefits. There are hardly any indications for removing it.
The contraindications of HRT are outlined in Figure 3.
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6. The Role of Other Hormones Secreted by the Ovary
A functional ovary secretes several hormones, which play an essential role in the maintenance
of women’s health and well-being; however, they are not a part of the current HRT regimens.
The advancements in science and technology have helped us in identifying and isolating many
of them. The ovarian hormones can be divided into two broad categories on the basis of their chemical
structure. The first group is formed by the steroid hormones, which include oestrogens, androgens and
progestins. The next group is the peptide hormones, which includes AMH, inhibin, activin, follistatin,
IGF, relaxin, transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), epidermal growth
factor (EGF) and the oocyte-derived proteins GDF-9 and BMP-15. The levels of activin increase after
menopause, follistatin concentrations remains the same [104,105] and the levels of all other hormones
decrease. Most of them are released into the circulation and can be detected systemically. Factors such
as IGF, GDF-9 and BMP-15 are released locally and act to promote follicular growth [1].
6.1. Androgens
In premenopausal women, levels of free testosterone are found to correlate directly with
libido [106]. After menopause, though the androgen production continues, its levels are much lower
than the women of the reproductive age group. Supplementation of androgen has been found to
increase not only the sexual desire but also improve the psychological well-being [107,108]. Along with
that, androgen boosts have helped postmenopausal females to increase bone density more than
oestrogen alone. However, the benefits of adding androgens must be weighed against their undesirable
effects like hirsutism and hypercholesterolemia [109,110].
6.2. Anti-Müllerian Hormone
Anti-Müllerian hormone (AMH also called Müllerian inhibiting substance (MIS)) is secreted in
the ovary by the granulosa cells of preantral and small antral follicles [111]. It regulates the follicular
development in an autocrine and paracrine manner. Several studies on AMH have found that it inhibits
the proliferation of all gynaecological cancers expressing MIS receptor such as cervical, endometrial,
ovarian and breast cancers [112–115]. MIS inhibits the cancer cells by interfering with cell cycle
progression and inducing apoptosis in them. The lack of AMH after menopause could be one of
the contributors to the increased incidence of gynaecological carcinomas postmenopausally and its
supplementation could have a preventable role in their development. It could also be contemplated
that AMH may play a possible role in treating gynaecological conditions like endometriosis and
adenomyosis. Pepin et al., have recently used adeno-associated virus (AAV9) to deliver MIS in mice
which significantly inhibited the growth of ovarian cancer cells [116]. Papakostas et al., developed a
novel and efficient way of producing highly pure and biologically active internally labelled form of
MIS [117]. This provides a ray of hope that incorporating AMH in HRT in the near future could make
it better and closer to a functional ovary.
6.3. Inhibin
Inhibin is secreted by the granulosa cells of small antral follicles during the follicular phase and
helps in folliculogenesis [111]. It has been found that inhibin knockout mice have a higher susceptibility
to developing tumours of gonads and adrenals. This suggests a potential tumour suppressive effect
of inhibin in the body [118,119]. Recombinant human inhibin has long been synthesised [120] and its
addition to HRT may prove beneficial. There have been no studies done thus far; however, there is a
potential for research on the topic.
6.4. Insulin-Like Growth Factor
IGFs are single-chain polypeptides, which resemble insulin in structure and function and are
secreted by granulosa cells in response to follicular stimulating hormone (FSH). In humans, IGF-II is
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more active in the embryonic period while IGF-I postnatally [1]. The ovary produces high amounts
of IGF-I, next only to the liver. IGF along with TGF-β is required for maintaining healthy bone
mass. Recombinant human IGF-I has been synthesised in the laboratory, and there are promising
studies regarding its use in cardiovascular diseases [121] and diabetes mellitus [122]. It would also be
worthwhile conducting further studies to explore the potential effects of supplementing IGF in the
postmenopausal state.
6.5. Relaxin
Relaxin is a pleiotropic hormone secreted by ovary with a role in a multitude of physiological
processes besides reproduction and pregnancy. It has positive effects on almost every organ system of
the body, including the brain, heart and kidney. It has a central vasopressor effect and anti-ischemic
effect on brain and myocardium [123,124]. It has a relaxant effect on the vasculature mediated by nitric
oxide secreted from the endothelial cells [125–127]. Moreover, it induces angiogenesis and inhibits
the activation of inflammatory cells thus playing a key role in the prevention of CHD [128]. It is
found to impede myocardial damage induced by ischaemia and reperfusion [129–131]. It inhibits
platelet aggregation [132] and neutrophil activation [133,134]. The loss of protection against CHD in
postmenopausal women is partly attributed to the loss of relaxin. Relaxin is anti-asthmatic [135,136]
and promotes ciliary beating in the respiratory pathways [137]. Recombinant human relaxin (Serelaxin)
has been successfully tried in patients with acute heart failure, and resulted in reduced mortality,
symptom relief and improvement in clinical outcomes [138,139].
7. Limitations of Current HRT
Hormone replacement therapy is undoubtedly beneficial in postmenopausal women with
symptoms of hormone deprivation, but it has its own limitations. Although the ovary secretes
a multitude of hormones, only two of them, oestrogen and progesterone, are replaced by HRT.
Also, the pharmacokinetics of the synthetic hormones makes them substantially different from
the natural ones. Not only does the number and type of hormones given in HRT matter, but the
route of delivering these hormones so as to resemble physiologically is also imperative. The oral
preparations of oestrogen and progestin have a significant first-pass metabolism, which decreases
the bioavailability of the hormones. Once oestrogen is metabolised in the liver, it gets converted to
oestrone sulphate (a weak oestrogen), and subsequently, only 10% of it reaches the circulation [140].
Orally administered oestrogen also increases sex hormone binding globulin (SHBG) levels [141,142],
which further reduces the bioavailability, not only of the exogenous hormone but also of the residual
endogenous one. Although HRT could, to some extent, compensate for the loss of ovarian hormone
production, the delivery of constant amount via pharmacological means leads to substantially higher
concentrations of the hormones, causing various side effects. In the body, the levels of different
hormones secreted by the ovary vary not only with the phase but also within each day of the menstrual
cycle, regulated by various feedback mechanisms.
8. Emerging Opportunities
8.1. Cell-Based Hormone Delivery
An approach to providing all the ovarian hormones physiologically without causing any side
effects would be cell-based hormone delivery. This concept of designing an artificial ovary involves
dissecting all the cells in the ovary and subsequently amalgamating them. This would unveil the
contribution of each component of the ovary and may prove clinically useful in devising an optimal
HRT. Though several types of research have been undertaken, the complex, cyclical and dynamic
functioning of the ovary makes the formation of an artificial ovary a tough task. In a study, theca and
granulosa cells, after being isolated, were seeded into micro-moulded gels and self-assembled into
complex 3D microtissue [143]. The oocytes thus created from this construct of artificial ovary were
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functional and could be used to replace the lost ovarian function in postmenopausal women, as they
can secrete hormones in response to gonadotropins.
Sittadjody et al., devised an in vitro tissue-based technique of hormone delivery that used a
functional construct manufactured utilising encapsulation technology [144]. They consolidated theca
and granulosa cells isolated from rat ovaries to form the native follicular structure using multi-layered
alginate microcapsules. The encapsulated cells were viable and secreted adequate levels of oestradiol,
progesterone, activin and inhibin in response to FSH and luteinising hormone (LH). This suggested
that the multilayer microcapsules could function as a potential tissue-engineered endocrine ovary
by synchronizing with the innate hypothalamic-pituitary-ovarian (HPO) axis. The same authors
also suggested that the addition of a layer of poly L-ornithine around the theca cells will protect
the construct from the host immune system and enable its in vivo use as a graft in postmenopausal
women. The cell encapsulation technique may prove to be efficient in delivering the cultured cells
into the body. This opens a whole new platform for further research in administering HRT. A similar
experiment done in ovariectomized mice using granulosa cells grown on microcarriers, enclosed
with theca cells in alginate-chitosan-alginate microcapsules have shown normal levels of serum
estradiol and progesterone [145]. Another group has successfully used allografted microencapsulated
ovarian cells in vivo to prevent the risk of osteoporosis after ovariectomy in mice [146]. The tissue
engineering approaches might prove promising to provide endogenous female hormones in symptomatic
post-menopausal females.
8.2. Brain-Selective Oestrogen Therapy
Recently, Merchenthaler et al. discovered that oral administration of a human oestrogen
precursor—10β,17β-dihydroxyestra-1,4-dien-3-one (DHED) alleviates hot flushes and restores the
oestrogen deprivation-induced loss of diurnal rhythm in rat models of thermoregulatory dysfunction
of the brain [147,148]. Oestrogen is selectively generated in the brain, independent of the route of
administration, and thus avoids the detrimental effects of the hormone exposure in the rest of the body,
including the uterus, and circumventing the need for progesterone supplementation. However, further
studies are required in the field before it can be clinically applied.
8.3. Ovarian Tissue Transplantation
Furthermore, studies conducted using mice models have shown that transplantation of young
ovaries to old mice increases their lifespan [149,150]. The same authors also found that mice that had
ceased cycling before ovarian transplantation showed an increase in lifespan compared with mice still
cycling at transplantation. Shikanov et al., transplanted ovarian cortical tissue in mice. The cortical
tissue was vitrified, thawed and then encapsulated in fibrin-alginate hydrogels. It was loaded with
vascular endothelial growth factor (VEGF) and then placed the tissue in the bursal sac [151,152].
The biomaterial supported cell infiltration and thus promoted the integration of the graft with the host.
VEGF enhanced angiogenesis with vessel growth primarily from the bursa and thus, they obtained a
high degree of graft revascularisation. Few studies have also been conducted in humans, transplanting
young healthy ovaries using cortical grafting technique from premenopausal monozygotic twins
discordant for premature ovarian failure and successful fertility outcomes were reported [153].
There was a case reported in which a woman with Hodgkin’s lymphoma was auto-transplanted
her own ovary heterotopically subcutaneously in the abdomen after receiving hematologic stem cell
transplantation. She successfully regained her fertility and had three babies [154]. The technique can
be used in a postmenopausal woman by removing and cryopreserving one of her ovaries after she
completes the childbearing process and then auto-transplanting the ovarian tissue at menopause. It is
too early to say whether the benefits of such techniques outweigh the risks. This area needs to be
studied further and could prove to be a breakthrough in the treatment of postmenopausal women.
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9. Conclusion
The review outlines the strengths and weaknesses of HRT and highlights the potential areas for
future research. The inadequate symptom relief and side effects associated with current HRT continues
to set new riddles and opens a whole era to explore options to reformulate the current HRT. An ideal
HRT should supplement all the hormones secreted by a functional ovary in a physiological manner
without any side effects. There is tremendous potential for research in this field to understand the
collective roles of the various ovarian hormones and to devise an auto-regulated hormone delivery
system which replicates the normal physiology. Its clinical applications can prove to be transformative
for postmenopausal women helping them to lead a healthy and productive life.
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